Revolution Medicines (RVMD) Enterprise Value (2018 - 2025)
Revolution Medicines (RVMD) has 7 years of Enterprise Value data on record, last reported at -$2.0 billion in Q4 2025.
- For Q4 2025, Enterprise Value rose 11.52% year-over-year to -$2.0 billion; the TTM value through Dec 2025 reached -$2.0 billion, up 11.52%, while the annual FY2025 figure was -$2.0 billion, 11.52% up from the prior year.
- Enterprise Value reached -$2.0 billion in Q4 2025 per RVMD's latest filing, down from -$1.9 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$201.3 million in Q3 2024 and bottomed at -$2.3 billion in Q4 2024.
- Average Enterprise Value over 5 years is -$1.2 billion, with a median of -$861.3 million recorded in 2023.
- Peak YoY movement for Enterprise Value: surged 75.25% in 2024, then tumbled 859.7% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$577.1 million in 2021, then fell by 11.76% to -$644.9 million in 2022, then tumbled by 187.31% to -$1.9 billion in 2023, then dropped by 23.55% to -$2.3 billion in 2024, then grew by 11.52% to -$2.0 billion in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$2.0 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$2.1 billion in Q2 2025.